Halozyme raises $1.5B converts; $1.02B note repurchase, capped calls
Rhea-AI Filing Summary
Halozyme Therapeutics completed a $1.5 billion convertible note financing, split between $750.0 million of 0% Convertible Senior Notes due 2031 and $750.0 million of 0.875% Convertible Senior Notes due 2032, including full exercise of the Initial Purchasers’ options.
The company received net proceeds of approximately $1.47 billion. It used about $182.7 million for capped call transactions and paid approximately $1.020 billion in cash to repurchase portions of its 2027 and 2028 convertible notes. The remaining proceeds are earmarked for general corporate purposes, potential acquisitions and strategic transactions, and potential future note repurchases or repayment at maturity.
The notes are convertible at an initial rate of 11.4683 shares per $1,000 (conversion price ~$87.20). The 2032 notes bear 0.875% interest, paid semi‑annually starting May 15, 2026; the 2031 notes bear no regular interest. Capped calls carry an initial cap price of $136.78 per share. Holders have customary conversion windows and protections, including Fundamental Change repurchase rights and Make‑Whole adjustments, under the new indentures.
Positive
- None.
Negative
- None.
Insights
$1.5B converts refinance near-term notes; dilution mitigated by capped calls.
Halozyme issued two tranches of converts: $750.0M due 2031 at 0% and $750.0M due 2032 at 0.875%. Net proceeds were about $1.47B. The company repurchased approximately $1.020B of 2027/2028 notes and entered capped calls costing about $182.7M.
The initial conversion rate is 11.4683 shares per $1,000 (conversion price ~$87.20), with capped calls initially capped at $136.78. This structure limits potential share issuance within the cap while extending maturities and modestly increasing fixed cash interest (only on the 2032s).
Key mechanics include semiannual interest on the 2032s beginning May 15, 2026, Fundamental Change repurchase rights at 100% of principal, Make‑Whole provisions, and redemption restrictions until 2029. Actual dilution depends on stock price versus the conversion price and cap.
8-K Event Classification
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did HALO announce in this 8-K?
How much cash did HALO receive and how was it used?
What are the conversion terms for HALO’s new notes?
What interest will HALO pay on these notes?
What is the capped call cap price?
What protections do noteholders have?
How will remaining proceeds be used by HALO?
AI-generated analysis. How Rhea-AI works. Not financial advice.